Akebia Therapeutics (AKBA) has shared an announcement.
Akebia Therapeutics, Inc. is set for a leadership change as Senior Vice President and Chief Financial Officer Ellen Snow prepares to step down on March 22, 2024. She will receive a severance package that includes 12 months of her base salary and potential COBRA premium reimbursements, in line with her existing Executive Severance Agreement. Her unvested equity will also continue to vest during this period. The company’s President and CEO, John Butler, will take over her responsibilities on an interim basis, leveraging his extensive experience from previous leadership roles in the biopharmaceutical industry.
For an in-depth examination of AKBA stock, go to TipRanks’ Stock Analysis page.
